Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
monoclonal_antibody
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04266912CT.gov Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03941262CT.gov Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy | — | Completed | — | — | — |
NCT03451825CT.gov Phase I/II Study of Avelumab in Pediatric Cancer Participants | — | Terminated | — | — | — |
NCT03217747CT.gov Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Refractory Malignant Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Avelumab (this asset) | M.D. Anderson Cancer Center | P1/2 | CCC · 48 |
| Catequentinib | Nanfang Hospital, Southern Medical University | P3 | BB |
| Irinotecan | M.D. Anderson Cancer Center | P2 | BB |
| Durvalumab | OHSU Knight Cancer Institute | P2 | BB |
| Cediranib | National Cancer Institute (NCI) | P2 | BB |
| Nivolumab | CatalYm GmbH | P2 | BB |
| Olaparib | Fundación de investigación HM | P2 | BB |
| Sugemalimab | Second Affiliated Hospital of Soochow University | P2 | BB |
| Gm-Csf | Second Affiliated Hospital of Soochow University | P2 | B |
+42 more in the Refractory Malignant Neoplasm cohort
Other indications for Avelumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P3 | B · 58 |
| Urothelial Carcinoma | — | P3 | B · 58 |
| Bladder Transitional Cell Carcinoma | — | P3 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Avelumab in Refractory Malignant Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/avelumab-refractory-malignant-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →